---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-25-006186"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2025-05-19T23:59:59+00:00"
generated_at: "2026-05-21T01:59:51.610012+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma closes acquisition of RP LLC; $200M cash, shares, and $380M debt assumed

## Summary
- Paid $200M cash plus 24,530,266 non-voting Class E shares; assumed RP Management's $380M term loan.
- Share consideration to Pablo Legorreta vests over 5 years; other management members vest over 10 years.
- Joinder of Royalty Pharma Holdings Ltd and RP LLC as borrowers under existing $380M term loan; RP Management released.
- Amended exchange agreement allows recipients to exchange RPH non-voting shares for Royalty Pharma Class A shares.
- Amended articles of association of Royalty Pharma plc and RPH to reflect new share classes and procedural refinements.

## SEC filing metadata
- accession: 0000950103-25-006186
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2025-05-19T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.01, 1.01, 2.03, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000095010325006186/0000950103-25-006186-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000095010325006186/dp228958_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-25-006186
- JSON: https://secwatch.observer/filing/0000950103-25-006186.json
- Plain text: https://secwatch.observer/filing/0000950103-25-006186.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.